Methods of Cancer Diagnosis, Therapy and Prognosis: General Methods and Overviews, Lung Carcinoma and Prostate Carcinoma

Copertina anteriore
M. A. Hayat
Springer Science & Business Media, 21 nov 2008 - 602 pagine
Cancer is the leading cause of death, in the number of older cancer patients is after cardiovascular diseases, in the expected. Approximately, 77% of all types United States. A total of ? 1,399,790 new of cancers are diagnosed in persons of 55 cancer cases and ? 564,830 deaths were years and older. It was estimated that o- reported in the year 2006 in the country. third of the 559,650 cancer deaths in 2007 Approximately, one in every two men and in the United States were related to ov- one in every three women in the country weight or obesity, physical inactivity, and will have some type of cancer during nutrition, and thus could also be prevented their lifetime. Healthcare costs exceed (Am. Cancer Society, 2007). However, 1. 7 trillion dollars per year in the United in developed countries, including United States, which is ? 15% of the country’s States, the average person of 65 years can gross domestic product. expect to live another 15 years in a fairly Tobacco use is the most serious prevent- good health. Persons of 75 or 85 years old able cause of cancer. Tobacco use causes have an average expectancy of 10 and 6 cancer of the lung, throat, mouth, pancreas, years, respectively. urinary bladder, stomach, liver, kidney, and During the last three decades, intensive other types. Passive smoking causes lung clinical research has resulted in reduced cancer.
 

Sommario

Clinicopathologic Features
3
Detection of Circulating Cancer
12
Detection of Recurrent Cancer by Radiological Imaging
17
Treatment with DocetaxelEpirubicin
27
Gynecological Cancers Ovarian Cancer Endometrial Cancer Cervical Cancer Head and Neck Cancers
33
Distant Metastasis in Elderly Patients with
42
Role of TP53 Mutations in Cancer An Overview
75
Personalized Medicine for Cancer Sarah J Welsh and Garth Powis
93
Pathology
363
CD56
377
Gefitinib Response of Brain Metastases from NSCLC References
383
The Role of Intermediary Metabolism and Molecular Genetics
397
The Citrate Relationship in Prostate Cancer
403
Neoadjuvant Treatment
408
Are Breast Cancer Survivors at Risk for Developing
409
ArrayBased Comparative Genomic Hybridization
415

7
109
Index
119
Cancer Vaccines and Immune Monitoring An Overview Zsuzsanna Tabi and Stephen
129
Combined RadioImmunotherapy
145
Summary
154
New Insights into the Role of Infection Immunity and Apoptosis
161
10
179
An Overview
193
Lung Carcinoma
203
Pulmonary
207
Breast
215
15
235
Pneumonia
236
Atelectasis
242
Diagnostic Workup
251
17
261
129
266
SecondLine Treatment
269
Epidemiology
281
EGFR Gene Mutations
291
Oncogene Addiction and Gefitinib Response
298
Acquired
307
22
317
Prognosis Using the
323
Pathological Distinction of Pulmonary Large Cell Neuroendocrine
349
Fusion Genes Newly Discovered Players
424
Role of Vav3 Overexpression in Development
431
Prognostic Markers in Prostatic Carcinoma
465
Detection of Free TumorSpecific DNA in Blood
481
Relevance of DoseIntensity for Adjuvant Treatment
487
PlasmaBased Epigenetic Analysis
493
Prostate Carcinoma
499
Color Doppler Ultrasound
507
16b18FFluoro5αDihydrotesteroneFDHT
521
Effects of Standard Treatments on the Immune Response
531
References
551
Results Discussion
558
236
563
Magnetic Resonance Imaging
565
The Ottawa Phase II Intermittent Androgen Suppression Experience
567
Is There an Accepted Standard Regimen of Intermittent Androgen
573
432
575
566
586
TTF1
589
567
592
Prophylactic Cancer Vaccines
596
References
597
207
599
Copyright

Altre edizioni - Visualizza tutto

Parole e frasi comuni

Informazioni bibliografiche